ArticleBMC medical imaging2026
Development of multiphasic CT-based delta-radiomics model for predicting postoperative recurrence risk in bladder cancer.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study aimed to develop a CT-based delta-radiomics model for personalized prediction of postoperative prognosis in bladder cancer patients and identification of differentially expressed genes associated with tumour recurrence. MATERIALS AND
methodsThis retrospective study included 316 patients with bladder cancer from Wuhan Union Hospital who underwent preoperative unenhanced and arterial-phase CT before surgical resection. Patients were randomly divided into training and internal validation cohorts at an 8:2 ratio. Radiomic features were extracted from tumor volumes of interest on both CT phases, and delta-radiomic features were calculated as arterial-phase features minus unenhanced-phase features. Feature selection was performed within the training cohort using statistical filtering, correlation analysis, and LASSO regression. Multiple machine-learning classifiers were evaluated, and a combined clinico-radiomic model was constructed by integrating the delta-radiomics score with selected clinical predictors. Model performance was assessed using ROC analysis, calibration, decision curve analysis, DeLong testing, and repeated stratified random splitting. An additional TCIA cohort of 33 patients was used for exploratory transcriptomic analysis.
resultsAfter feature selection, nine delta-radiomic features derived from paired unenhanced and arterial-phase CT images were retained for model construction. The LightGBM-based delta-radiomics model achieved AUCs of 0.837 and 0.822 in the training and validation cohorts, respectively. The combined clinical-radiomics model, constructed by integrating the delta-radiomics Rad-score with muscle invasion as a clinical predictor, achieved the best discrimination, with AUCs of 0.860 and 0.861 in the training and validation cohorts, respectively, and showed stable validation performance in 100 repeated splits. High radiomics scores were associated with significantly shorter recurrence-free survival. Exploratory transcriptomic analysis showed enrichment of immune-related pathways in the low-risk radiomic subgroup.
conclusionsMultiphasic CT-based delta-radiomics provides a non-invasive approach for predicting postoperative recurrence and stratifying prognosis in bladder cancer. A combined clinico-radiomic model incorporating delta-radiomics and muscle invasion achieved superior predictive performance and may support individualized postoperative risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.